[{"uuid": "bbd7fc4a-a76c-3b3e-b9e0-4b3b50b8bba2", "title": "BofA Adjusts Price Target on Axsome Therapeutics to $143 From $122", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/bofa-adjusts-price-target-axsome-152254779.html", "providerPublishTime": 1738596174, "type": "STORY"}, {"uuid": "7950efc7-0bf3-3ff3-80c1-a937eb670407", "title": "Truist Securities Adjusts Axsome Therapeutics Price Target to $190 From $180, Maintains Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/truist-securities-adjusts-axsome-therapeutics-140900225.html", "providerPublishTime": 1738591740, "type": "STORY"}, {"uuid": "c401b938-5904-3554-b76b-d843b6fbb18d", "title": "Mizuho Raises Price Target on Axsome Therapeutics to $137 From $122, Keeps Outperform Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/mizuho-raises-price-target-axsome-125624378.html", "providerPublishTime": 1738587384, "type": "STORY"}, {"uuid": "354be1f3-1895-31ed-9886-794296c00cc8", "title": "RBC Lifts Price Target on Axsome Therapeutics to $143 From $139, Keeps Outperform Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/rbc-lifts-price-target-axsome-122925209.html", "providerPublishTime": 1738585765, "type": "STORY"}, {"uuid": "75dc85f7-7a55-3ab4-89cc-cf80c9af21c3", "title": "Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/axsome-gets-fda-nod-migraine-155100511.html", "providerPublishTime": 1738338660, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/L9oXp_PBujUXs0r0RIkKrg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AXSM"]}, {"uuid": "895aa982-dd24-324d-8973-f64010e461bd", "title": "Axsome Therapeutics Hosts SYMBRAVO\u00ae FDA Approval Virtual Investor Event with Expert Thought Leader", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/axsome-therapeutics-hosts-symbravo-fda-120000118.html", "providerPublishTime": 1738324800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RW9dIS08rGlshoyfw2yAIA--~B/aD0xMjU7dz0yMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 222, "height": 125, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SnT.GTGukc_xLCyR5loNSw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AXSM"]}, {"uuid": "d74995ed-62fe-3e45-843b-aa25a3e85b16", "title": "Axsome Therapeutics Announces FDA Approval of SYMBRAVO\u00ae (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/axsome-therapeutics-announces-fda-approval-204500009.html", "providerPublishTime": 1738269900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RW9dIS08rGlshoyfw2yAIA--~B/aD0xMjU7dz0yMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 222, "height": 125, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SnT.GTGukc_xLCyR5loNSw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AXSM"]}, {"uuid": "e9ed142a-e86f-3f8d-b598-3cb20e920e32", "title": "Axsome Shares Rise 19% in a Month: What's Driving the Rally?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/axsome-shares-rise-19-month-153200859.html", "providerPublishTime": 1737732720, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/W7_U.zwAlTUJvDO9hN5kQQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "ca8a2b87-e756-3562-834d-87efaa4e7319", "title": "Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/axsome-therapeutics-report-fourth-quarter-120000766.html", "providerPublishTime": 1737547200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RW9dIS08rGlshoyfw2yAIA--~B/aD0xMjU7dz0yMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 222, "height": 125, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SnT.GTGukc_xLCyR5loNSw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AXSM"]}, {"uuid": "4c257343-36bb-323a-a181-a3f97253684e", "title": "Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/axsome-axsm-moves-11-5-140500391.html", "providerPublishTime": 1736863500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dHEXrxG0jHU8_aZ1QyyUfw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d09a586ae00ecb333775f9766ec152a7", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/bZxeP49qJt6fWkCptq2oKg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d09a586ae00ecb333775f9766ec152a7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MIRM"]}, {"uuid": "eeecc0e9-f9de-37b2-80b5-85ec325dc29c", "title": "Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/axsome-therapeutics-provides-preliminary-fourth-120000827.html", "providerPublishTime": 1736769600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RW9dIS08rGlshoyfw2yAIA--~B/aD0xMjU7dz0yMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 222, "height": 125, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SnT.GTGukc_xLCyR5loNSw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AXSM"]}, {"uuid": "0c76eb68-d211-361c-9926-d2b180417f25", "title": "Can Analysts Pick Stocks? I Doubt It", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/analysts-pick-stocks-doubt-162204972.html", "providerPublishTime": 1736785324, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Y4gluffW4ohl4mzd9tnd5g--~B/aD0zNjY7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/772740eaffb8e863e2e0ea40286fc545", "width": 550, "height": 366, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/TjL8be4Vd0Z_jlMg7C.CkA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/772740eaffb8e863e2e0ea40286fc545", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SLB"]}]